Delivery Order SPE2DR25D6028-SPE2DR26FASHF
- Not listed
- The Defense Logistics Agency awarded a delivery order valued at $1,233.19 to AmerisourceBergen Drug Corp for Infed 100 mg/2 mL vials on December 2, 2025, with an ultimate completion date of December 3, 2025. This firm fixed price delivery order was competitively awarded with no set-aside designation and represents a continuation of the vendor's pharmaceutical supply relationship with the federal government. The work will be performed at AmerisourceBergen's corporate office location in...
- The Defense Logistics Agency awarded a $11,418.72 delivery order to AmerisourceBergen Drug Corp for Infed 100 mg/2 ml vials on October 31, 2025, with an ultimate completion date of November 3, 2025. This is a firm fixed price, non-competitive set-aside contract for pharmaceutical supply to be performed at the contractor's Conshohocken, Pennsylvania facility. The delivery order is issued under AmerisourceBergen's larger Indefinite Delivery Contract (IDC) with DLA Troop Support Medical, valued...
- The Defense Logistics Agency awarded a delivery order valued at $8,093.02 to AmerisourceBergen Drug Corp on July 19, 2025, for the supply of Infed 100 mg/2 mL vials. The award is a firm fixed price, non-set-aside contract with a completion date of July 21, 2025, with performance to be fulfilled at the contractor's facility in Conshohocken, Pennsylvania. This delivery order represents a small transaction within the federal medical supply procurement framework supporting military and veteran...
- The Defense Logistics Agency (DLA) Medical Supply Chain awarded a delivery order valued at $7,020.32 to AmerisourceBergen Drug Corp for the supply of Infed 100 mg/2 mL vials. This competitively awarded, firm fixed-price delivery order was issued on July 28, 2025, with an ultimate completion date of July 29, 2025, and will be performed at the contractor's Corporate Office location in Conshohocken, Pennsylvania. As a child delivery order under a larger contract vehicle, this award represents a...
- The Defense Logistics Agency (DLA) awarded a delivery order valued at $5,116.60 to AmerisourceBergen Drug Corp for the supply of Infed 100 mg/2 mL vials on December 3, 2025, with an ultimate completion date of December 4, 2025. This is a firm fixed price delivery order with no set-aside designation, indicating it was awarded through open competition. The work will be performed at AmerisourceBergen's corporate office location in Conshohocken, Pennsylvania. This delivery order is issued under...
- This federal contract award was issued by the Defense Logistics Agency (DLA) to Amerisourcebergen Drug Corp, a major pharmaceutical distributor and healthcare solutions provider. The $2,177.00 firm-fixed-price delivery order contract is for the supply of INFED 100 MG/2 ML VIAL 2ML, a medical product, with a performance period through September 12, 2024. The contract is not set aside and allows for the delivery of a range of pharmaceutical and medical products to support military and federal...
- This federal contract award was issued by the Defense Logistics Agency (DLA) to AmerisourceBergen Drug Corp, a major pharmaceutical distributor and healthcare solutions provider. The $2,030.29 firm-fixed-price delivery order is for the supply of INFED 100 MG/2 ML VIAL 2ML, a pharmaceutical product. The contract has a performance period extending through June 23, 2025. AmerisourceBergen Drug Corp holds a larger $999,999,999.00 Indefinite Delivery Contract (IDC) with DLA Troop Support Medical,...
- This is a firm fixed price delivery order awarded by the Defense Logistics Agency (DLA) Troop Support Medical to the prime contractor Amerisourcebergen Drug Corp, a subsidiary of Amerisourcebergen Corporation. The contract is for the delivery of INFED 100 MG/2 ML VIAL 2ML, a pharmaceutical product, with a ceiling value of $2,177.10 and a period of performance through March 20, 2024. Amerisourcebergen Drug Corp is also the prime contractor on an indefinite delivery contract (IDC) with DLA Troop...
- The U.S. Department of Defense's Medical Supply Chain awarded a delivery order to AmerisourceBergen Drug Corp on April 24, 2025, for the supply of Infed 100 mg/2 ml vials. This competitively awarded, non-set-aside contract has a ceiling value of $9,315.83 and an ultimate completion date of April 25, 2025. AmerisourceBergen Drug Corp, a major pharmaceutical distributor headquartered in Conshohocken, Pennsylvania, will perform this work at its corporate office location. This delivery order is...
- AmerisourceBergen Drug Corp, a major pharmaceutical distributor headquartered in Conshohocken, Pennsylvania, received a delivery order valued at $6,453.60 from the Defense Logistics Agency (DLA) on June 18, 2025, for the supply of Injectafer 750 mg/15 mL vials. The contract is classified as a child award under a firm fixed-price delivery order arrangement with an ultimate completion date of June 20, 2025. No set-aside designation was applied to this award, indicating it was competitively awarded...
- SPE2DR25D6028Indefinite Delivery Contract
- SPE2DR25D6028-SPE2DR26FASHFDelivery Order
The Defense Logistics Agency awarded a delivery order to AmerisourceBergen Drug Corp on December 3, 2025, for the supply of Infed 100mg/2mL vials (10 count) with a ceiling value of $19,616.13. This firm fixed-price delivery order, with a completion deadline of December 31, 2025, represents a non-competed award under the company's existing Indefinite Delivery Contract with DLA. AmerisourceBergen Drug Corp, headquartered in Conshohocken, Pennsylvania, serves as a major pharmaceutical distributor and critical vendor for federal medical procurement, particularly supporting military and veteran healthcare systems through the DLA Medical Supply Chain. This delivery order is issued under AmerisourceBergen's prime Indefinite Delivery Contract (SPE2DX) with DLA Troop Support Medical, valued at $999,999,999.00 and extending through December 2026. The SPE2DX contract serves as a comprehensive global pharmaceutical support vehicle enabling the company to supply a broad range of pharmaceutical products and medical supplies, including specialty medications, brand-name and generic drugs, vaccines, and medical commodities across multiple therapeutic domains. The contract supports the Defense Health Agency, U.S. Coast Guard, and other government healthcare systems worldwide, with DLA planning future Pharmaceutical Prime Vendor Global Program Generation V contracts involving multiple regional award recipients.
Mod # | Description | ReasonForModification | Federal Obligation | Date |
|---|---|---|---|---|
| Not listed | Not listed | $19.6k | 12/2/25 |